E. Schott

1.3k total citations · 1 hit paper
36 papers, 753 citations indexed

About

E. Schott is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, E. Schott has authored 36 papers receiving a total of 753 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 16 papers in Epidemiology and 6 papers in Oncology. Recurrent topics in E. Schott's work include Hepatitis C virus research (19 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). E. Schott is often cited by papers focused on Hepatitis C virus research (19 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and Liver Disease Diagnosis and Treatment (9 papers). E. Schott collaborates with scholars based in Germany, United States and Spain. E. Schott's co-authors include Bruno Sangro, Olivier Rosmorduc, Philippe Merle, Damir Begic, Ann‐Lii Cheng, Philippe Mathurin, Jaclyn Neely, Thomas Yau, Julien Edeline and Richard S. Finn and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Journal of Hepatology.

In The Last Decade

E. Schott

33 papers receiving 743 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

2019 497 citations Thomas Yau, Richard S. Finn et al. Annals of Oncology profile →

Peers

Countries citing papers authored by E. Schott

Since Specialization

Citations

This map shows the geographic impact of E. Schott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Schott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Schott more than expected).

Fields of papers citing papers by E. Schott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Schott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Schott. The network helps show where E. Schott may publish in the future.

Co-authorship network of co-authors of E. Schott

This figure shows the co-authorship network connecting the top 25 collaborators of E. Schott. A scholar is included among the top collaborators of E. Schott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Schott. E. Schott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma 2020 ·Annals of Oncology ·Bruno Sangro, (unknown), Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang‐Hyub Han, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, E. Schott, Su Pin Choo, Robin Kate Kelley, Damir Begic, (unknown), Jaclyn Neely, Marina Tschaika, Thomas Yau	42
2	CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) breakdown → 2019 ·Annals of Oncology ·Thomas Yau, (unknown), Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang‐Hyub Han, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, E. Schott, Su Pin Choo, Robin Kate Kelley, Damir Begic, (unknown), Jaclyn Neely, Jeffrey Anderson, Bruno Sangro	497
3	Beste supportive Behandlung bei Patienten mit therapie-refraktärem, hepatozellulären Karzinom (HCC) – Ergebnisse einer Delphi-Studie 2017 ·Zeitschrift für Gastroenterologie ·Jörg Trojan, Thomas Berg, Peter Buggisch, E. Schott, Ingo Tamm, Manfred Welslau, Alexander S. Vogel	0
4	Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study 2016 ·Journal of Hepatology ·Katja Deterding, Christoph D. Spinner, E. Schott, Tania M. Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Markus Cornberg, Andreas Umgelter, (unknown), Stefan Zeuzem, Heiko von der Leyen, (unknown), M.P. Manns, H. Wedemeyer	6
5	Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study 2016 ·Zeitschrift für Gastroenterologie ·Katja Deterding, Christoph D. Spinner, E. Schott, Tania M. Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Markus Cornberg, Andreas Umgelter, (unknown), Stefan Zeuzem, Heiko von der Leyen, (unknown), (unknown), Heiner Wedemeyer	3
6	Stopping Tenofovir Disoproxil Fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial („FINITE CHB“) 2015 ·Zeitschrift für Gastroenterologie ·Thomas Berg, Krzysztof Simon, Stefan Mauss, E. Schott, R Heyne, Dietmar M. Klass, Christoph Eisenbach, (unknown), (unknown), G Felten, Julian Schulze zur Wiesch, Markus Cornberg, (unknown), L Gallo, Tobias Warger, John Asger Petersen	2
7	268 SAFETY AND TOXICITY OF THE COMBINATION OF Y90-RADIOEMBOLIZATION AND SORAFENIB IN ADVANCED HCC: AN INTERIM ANALYSIS OF THE EUROPEAN MULTICENTER TRIAL SORAMIC 2013 ·Journal of Hepatology ·Jens Ricke, (unknown), Jerzy Walecki, E. Schott, Bruno Sangro, (unknown), Holger Amthauer, Chris Verslype, Peter Reimer, Kerstin Schütte, (unknown), Peter Malfertheiner	4
8	908 REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY 2013 ·Journal of Hepatology ·Ulrich Spengler, (unknown), C John, (unknown), R Heyne, Christoph Antoni, (unknown), E. Schott, (unknown), (unknown), D. Hueppe, U. Alshüth, (unknown), Peter Buggisch	1
9	871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY 2013 ·Journal of Hepatology ·(unknown), Klaus Boeker, Christoph Eisenbach, Bernd Moeller, (unknown), Thomas A. Lutz, (unknown), Stefan Christensen, M. Jung, G Teuber, (unknown), Marcus Schuchmann, E. Schott, U. Alshüth, D. Hueppe	1
10	Prädiktive Baseline Faktoren bei Patienten mit Zirrhose für den Therapieerfolg einer dualen Therapie mit Peginterferon alfa-2a (PEG) plus Ribavirin (RBV), was zählt? 2013 ·Zeitschrift für Gastroenterologie ·D. Hueppe, Stefan Mauss, (unknown), Andreas Schober, (unknown), Albrecht Stoehr, (unknown), (unknown), Axel Baumgarten, R Heyne, C John, Christoph Eisenbach, (unknown), E. Schott, G Teuber, Warren N. Schmidt, U. Alshüth, E Zehnter	1
11	52 DESCRIPTION OF AN AUTOMATED LOW-FLOW ASCITES (ALFA) PUMP SYSTEM FOR THE TREATMENT OF REFRACTORY ASCITES IN PATIENTS WITH CIRRHOSIS. PRELIMINARY REPORT 2012 ·Journal of Hepatology ·Pablo Bellot, (unknown), Germán Soriano, Markus von Schaewen, Beate Appenrodt, (unknown), (unknown), (unknown), Chris Verslype, Stefan Zeuzem, (unknown), Carlos Guarner, E. Schott, Tilman Sauerbruch, (unknown), Krum Katzarov, Frank Nevens, José M. Such	1
12	CD154, a marker of antigen‐specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection 2011 ·Journal of Viral Hepatitis ·(unknown), B Möller, Bertram Wiedenmann, Thomas Berg, E. Schott	17
13	Ischemic-Type Biliary Lesions After Ortothopic Liver Transplantation: Diagnosis With Magnetic Resonance Cholangiography 2011 ·Transplantation Proceedings ·Federico Collettini, Thomas Kroencke, Christoph Heidenhain, (unknown), Diane M. Renz, E. Schott, P. Neuhaus, Bernd Hamm, Alexander Poellinger	13
14	447 DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV) 2011 ·Journal of Hepatology ·Tracey Lutz, (unknown), (unknown), Axel Baumgarten, Christoph Eisenbach, Wolfgang Schmid, (unknown), Bernd Bokemeyer, Simon Pape, M. Roessle, Albrecht Stoehr, Jörn Andreas Lohmeyer, T. Witthoeft, B Möller, (unknown), E. Schott, U. Alshüth, D. Hueppe	0
15	79 SORAFENIB PLUS TACE FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA – FINAL RESULTS OF THE SOCRATES TRIAL 2011 ·Journal of Hepatology ·(unknown), (unknown), Michael Döllinger, E. Schott, Henning Wege, Michael Bitzer, C. Gog, (unknown), M. Schuchmann, Clemens Walter, D. Blondin, Christian Ohmann, Dieter Häussinger	8
16	Strategien zur Prävention des hepatozellulären Karzinoms bei der Hepatitis-Virus-Infektion 2008 ·Zeitschrift für Gastroenterologie ·E. Schott, A Bergk, Thomas Berg	5
17	709 LONG-TERM TREATMENT WITH LAMIVUDINE UP TO TEN YEARS: PREDICTIVE VALUE OF HOST AND VIRUS RELATED RISK FACTORS FOR THE DEVELOPMENT OF HBV RESISTANCE 2008 ·Journal of Hepatology ·Florian van Bömmel, (unknown), Ulrike Mihm, M.C. Jung, C. Sarrazin, A Bergk, B Schlosser, V Weich, Tobias Müller, E. Schott, Bertram Wiedenmann, Thomas Berg	1
18	Association of TLR7 single nucleotide polymorphisms with chronic HCV‐infection and response to interferon‐a‐based therapy 2007 ·Journal of Viral Hepatitis ·E. Schott, Heiko Witt, Konrad Neumann, A Bergk, Juliane Halangk, V Weich, Tobias Müller, Gero Puhl, Bertram Wiedenmann, Thomas Berg	65
19	Strategisches Projektmanagement 2005 ·DIAL (Catholic University of Leuven) ·E. Schott	3
20	Isatoribine, a toll-like receptor 7 agonist, significantly reduced plasma viral load in a clinical proof-of-concept study in patients with chronic hepatitis C virus infection. 2004 ·Hepatology ·Yves Horsmans, Thomas Berg, Jean‐Pierre Desager, Tobias Müller, E. Schott, Lisa Bauman, Kevin Steffy, Sophie Fletcher, (unknown), Wen‐Jinn Liaw, B. Kerr, D R Averett	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact